Wird geladen...
Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
Although GLP-1 (glucagon like peptide-1) based therapies (GLP-1 agonists and dipeptidyl peptidase-4 inhibitors) is currently playing a cornerstone role in the treatment of type 2 diabetes, dilemma does exist about some of its basic physiology. So far, we know that GLP-1 is secreted by the direct act...
Gespeichert in:
| Veröffentlicht in: | Indian J Endocrinol Metab |
|---|---|
| 1. Verfasser: | |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Medknow Publications & Media Pvt Ltd
2015
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4287769/ https://ncbi.nlm.nih.gov/pubmed/25593851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.146881 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|